Manufacturer Supply; High Purity and Competitive Price
Commercial Supply Formoterol Fumarate (CAS: 43229-80-7) Related Intermediates:
2-Bromo-4'-Benzyloxy-3'-nitroacetophenone CAS: 43229-01-2
[3-Nitro-4-(phenylmethoxy)phenyl]-oxirane CAS: 51582-41-3
1-(4-Methoxyphenyl)-2-benzylaminopropane CAS: 43229-65-8
| Chemical Name | 2-Bromo-4'-Benzyloxy-3'-nitroacetophenone |
| Synonyms | 1-(4-(Benzyloxy)-3-nitrophenyl)-2-bromoethanone |
| CAS Number | 43229-01-2 |
| CAT Number | RF-PI124 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C15H12BrNO4 |
| Molecular Weight | 350.16 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Light Yellow Powder |
| Purity / Analysis Method | ≥98.0% (HPLC) |
| Impurity | 2-Chloro-4'-Benzyloxy-3-Nitroacetophenone ≤1.0% |
| Impurity | 4'-Benzyloxy-3'-Nitroacetophenone ≤0.50% |
| Other Single Impurity | ≤0.50% |
| Moisture (K.F) | ≤0.50% |
| Test Standard | Enterprise Standard |
| Usage | Formoterol Fumarate (CAS: 43229-80-7) Intermediates |
2-Bromo-4′-Benzyloxy-3′-nitroacetophenone CAS: 43229-01-2 Synthesis Route
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. Commercial Supply Formoterol Fumarate (CAS: 43229-80-7) Related Intermediates:
2-Bromo-4'-Benzyloxy-3'-nitroacetophenone CAS: 43229-01-2
[3-Nitro-4-(phenylmethoxy)phenyl]-oxirane CAS: 51582-41-3
1-(4-Methoxyphenyl)-2-benzylaminopropane CAS: 43229-65-8
Formoterol Fumarate (CAS: 43229-80-7) is a β2-selective adrenergic agonist useful in the treatment of bronchial asthma. It s potency and duration of action a r e reported to exceed those of salbutamol, as is its ability to inhibit allergic and non-allergic histamine release.This is believed to result from formoterol's greater water solubility, allowing it to get to the receptor sites faster, whereas its moderate lipophilicity keeps it in the lungs longer. It is indicated for the long-term maintenance treatment of asthma and for patients with symptoms of nocturnal asthma who require regular treatment with inhaled, short-acting, β2-agonists. It is not indicated for patients whose asthma can be managed by occasional use of inhaled, short-acting, β2-agonists. Formoterol is available only as a powder in a capsule for administration via the aerosolizer. Patients should be cautioned not to take the capsules orally and to keep them in a safe place to avoid accidental oral administration.
